BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9312252)

  • 21. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
    Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
    van Nes JG; Putter H; Julien JP; Tubiana-Hulin M; van de Vijver M; Bogaerts J; de Vos M; van de Velde CJ;
    Breast Cancer Res Treat; 2009 May; 115(1):101-13. PubMed ID: 18484198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome.
    Iwaya K; Ogawa H; Izumi M; Kuroda M; Mukai K
    Virchows Arch; 2002 Jun; 440(6):589-93. PubMed ID: 12070597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
    Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
    Colleoni M; Zahrieh D; Gelber RD; Holmberg SB; Mattsson JE; Rudenstam CM; Lindtner J; Erzen D; Snyder R; Collins J; Fey MF; Thürlimann B; Crivellari D; Murray E; Mendiola C; Pagani O; Castiglione-Gertsch M; Coates AS; Price K; Goldhirsch A
    J Clin Oncol; 2005 Mar; 23(7):1390-400. PubMed ID: 15735115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of body mass index (BMI) to disease free (DFS) and distant disease free survivals (DDFS) among Turkish women with operable breast carcinoma.
    Demirkan B; Alacacioglu A; Yilmaz U
    Jpn J Clin Oncol; 2007 Apr; 37(4):256-65. PubMed ID: 17553816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular-biological markers as prognostic factors in breast cancer of I-IIA stage].
    Stepanova EV; Zagrekova EI; Ermilova VD; Turbin AD; Petrovichev NN; Vysotskaia IV; Dbar ZhN; Pashchenko NV; Baryshnikov AIu; Lichinitser MR
    Arkh Patol; 2003; 65(3):14-8. PubMed ID: 12879604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
    Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY
    Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome.
    Geara FB; Nasr E; Tucker SL; Charafeddine M; Dabaja B; Eid T; Abbas J; Salem Z; Shamseddine A; Issa P; El Saghir N
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):364-9. PubMed ID: 17324529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.